PT-141 dosage for women side effects include nausea, flushing, and headache. Learn the FDA-approved dose and safety tips for women and more today.
The FDA-approved PT-141 (bremelanotide) dosage for women is 1.75 mg injected subcutaneously into the abdomen or thigh, taken at least 45 minutes before anticipated sexual activity. The most common side effects are nausea, flushing, headache, and injection site reactions. PT-141 is not approved for men or for nasal spray use, and it should not be used more than once in 24 hours or more than 8 times per month.
What Is PT-141?
PT-141, also known as bremelanotide, is a synthetic peptide that activates melanocortin receptors in the brain. It is FDA-approved under the brand name Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD). PT-141 is not an aphrodisiac and does not work like hormone therapy. It must be prescribed by a healthcare professional.
PT-141 is given as a subcutaneous injection, not a pill. The drug is designed for use on an as-needed basis, not as a daily treatment.
FDA-Approved PT-141 Dosage for Women
The standard pt-141 dosage for women is 1.75 mg injected subcutaneously. This dose is fixed and does not change based on weight or age. Inject at least 45 minutes before sexual activity. Do not use more than one dose in 24 hours or more than eight doses in a month.
- Dose: 1.75 mg
- Route: subcutaneous injection (abdomen or thigh)
- Timing: 45 minutes before activity
- Maximum frequency: once per 24 hours, up to 8 times per month
There is no official pt-141 dosage calculator for women because the FDA-approved dose is always 1.75 mg. Online calculators that claim to customize dosing are not based on approved medical guidelines.
PT-141 Side Effects Women Commonly Report
Nausea is the most common side effect, affecting about 40% of women in clinical trials. Flushing and headache are also frequent. Most side effects are mild to moderate and fade within a few hours.
- Nausea (most common)
- Flushing (redness or warmth)
- Headache
- Injection site reactions (pain, bruising, itching)
- Temporary increase in blood pressure
- Hyperpigmentation (darkening of skin, gums, or breasts) with frequent use
A review of pt-141 side effects women have reported shows that nausea often improves after the first few doses. However, hyperpigmentation can be persistent and may not fade after stopping the drug. Understanding the potential side effects in women is important before starting treatment.
PT-141 Nasal Spray and Off-Label Dosing
PT-141 nasal spray is not FDA-approved. Early research studied intranasal bremelanotide for sexual dysfunction, but the approved version is only the injection. The pt-141 nasal spray dosage for women in those studies ranged from 10 mg to 20 mg, but absorption and effects varied. No nasal spray product is currently available by prescription in the US.
Some people ask about the dosage for women as a nasal spray, but the FDA has only approved the 1.75 mg subcutaneous injection. Off-label use of any form should be supervised by a doctor.
While PT-141 is not approved for men, some researchers have explored the pt-141 peptide dosage for men for erectile dysfunction. Those studies used doses ranging from 1.75 mg subcutaneous to 10–20 mg intranasal, but results are not definitive.
Comparing PT-141 Dosing Options
| Form | Typical Dose | FDA-Approved for Women? | Key Notes |
|---|---|---|---|
| Subcutaneous injection (Vyleesi) | 1.75 mg | Yes | Fixed dose; max 8 times per month |
| Intranasal (off-label) | 10–20 mg | No | Not available; variable absorption |
| Subcutaneous for men (off-label) | 1.75 mg or higher | No | Investigational; not recommended |
The table above shows that the only FDA-approved option for women is the 1.75 mg subcutaneous injection. Off-label and nasal spray options carry more uncertainty and should only be used under medical supervision.
Safety Warnings and When to Talk to a Doctor
PT-141 can raise blood pressure temporarily. Women with uncontrolled hypertension or cardiovascular disease should not use it. It is also not recommended for women who are pregnant or breastfeeding.
- Do not use with certain medications (e.g., MAO inhibitors, nitrates) without doctor approval.
- Avoid if you have kidney or liver disease.
- Report any skin darkening to your doctor immediately.
- Do not use more than 8 times per month.
Always consult a healthcare professional before using PT-141. This article is for informational purposes only and does not replace medical advice.
Frequently Asked Questions
What is the typical PT-141 dosage for women?
The FDA-approved dose for premenopausal women with HSDD is 1.75 mg injected subcutaneously at least 45 minutes before sexual activity. Do not exceed one dose in 24 hours or eight doses per month.
What are the most common side effects of PT-141 in women?
Nausea, flushing, headache, and injection site reactions are the most common side effects. Some women also experience temporary blood pressure increases or, with frequent use, skin darkening (hyperpigmentation).
Is PT-141 available as a nasal spray for women?
No, PT-141 nasal spray is not FDA-approved and no prescription nasal spray product is available in the US. Only the subcutaneous injection (Vyleesi) is approved for women.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.